Cargando…
Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study
[Image: see text]
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066752/ https://www.ncbi.nlm.nih.gov/pubmed/37013127 http://dx.doi.org/10.1002/ski2.150 |
| _version_ | 1785018326001385472 |
|---|---|
| author | Velin, Marine Cardot‐Leccia, Nathalie Cathelineau, Anne‐Claire Duteil, Luc Queille‐Roussel, Catherine Passeron, Thierry Bahadoran, Philippe |
| author_facet | Velin, Marine Cardot‐Leccia, Nathalie Cathelineau, Anne‐Claire Duteil, Luc Queille‐Roussel, Catherine Passeron, Thierry Bahadoran, Philippe |
| author_sort | Velin, Marine |
| collection | PubMed |
| description | [Image: see text] |
| format | Online Article Text |
| id | pubmed-10066752 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100667522023-04-02 Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study Velin, Marine Cardot‐Leccia, Nathalie Cathelineau, Anne‐Claire Duteil, Luc Queille‐Roussel, Catherine Passeron, Thierry Bahadoran, Philippe Skin Health Dis Letters to the Editor [Image: see text] John Wiley and Sons Inc. 2022-08-10 /pmc/articles/PMC10066752/ /pubmed/37013127 http://dx.doi.org/10.1002/ski2.150 Text en © 2022 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letters to the Editor Velin, Marine Cardot‐Leccia, Nathalie Cathelineau, Anne‐Claire Duteil, Luc Queille‐Roussel, Catherine Passeron, Thierry Bahadoran, Philippe Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study |
| title | Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study |
| title_full | Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study |
| title_fullStr | Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study |
| title_full_unstemmed | Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study |
| title_short | Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study |
| title_sort | efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: a prospective study |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066752/ https://www.ncbi.nlm.nih.gov/pubmed/37013127 http://dx.doi.org/10.1002/ski2.150 |
| work_keys_str_mv | AT velinmarine efficacyandsafetyof005ingenolmebutateinthetreatmentofbasalcellcarcinomaaprospectivestudy AT cardotleccianathalie efficacyandsafetyof005ingenolmebutateinthetreatmentofbasalcellcarcinomaaprospectivestudy AT cathelineauanneclaire efficacyandsafetyof005ingenolmebutateinthetreatmentofbasalcellcarcinomaaprospectivestudy AT duteilluc efficacyandsafetyof005ingenolmebutateinthetreatmentofbasalcellcarcinomaaprospectivestudy AT queillerousselcatherine efficacyandsafetyof005ingenolmebutateinthetreatmentofbasalcellcarcinomaaprospectivestudy AT passeronthierry efficacyandsafetyof005ingenolmebutateinthetreatmentofbasalcellcarcinomaaprospectivestudy AT bahadoranphilippe efficacyandsafetyof005ingenolmebutateinthetreatmentofbasalcellcarcinomaaprospectivestudy |